-
Je něco špatně v tomto záznamu ?
Terlipressin induced severe hyponatremia
M. Šíma, M. Pokorný, F. Paďour, O. Slanař
Jazyk angličtina Země Česko
Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2012
Medline Complete (EBSCOhost)
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- MeSH
- dospělí MeSH
- ezofageální a žaludeční varixy komplikace MeSH
- hematemeze farmakoterapie etiologie patofyziologie MeSH
- hyponatremie * chemicky indukované diagnóza terapie MeSH
- jaterní cirhóza komplikace MeSH
- lidé MeSH
- lypresin aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- vazokonstriktory aplikace a dávkování škodlivé účinky MeSH
- vodní a elektrolytová nerovnováha diagnóza etiologie prevence a kontrola MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- práce podpořená grantem MeSH
Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use - e.g. hyponatremia. We describe a case of a cirrhotic patient with active variceal bleeding treated during two separate hospitalizations with terlipressin. In both drug treatment periods, severe laboratory hyponatremia developed. After terlipressin discontinuation, mineral disbalance corrected rapidly. Positive dechallenge and rechallenge corresponding to the drug administration schedule confirms the causality between terlipressin administration and hyponatremia. Hyponatremia was preceded with substantial fluid retention in both episodes. In this case report we want to highlight the need for fluid balance monitoring immediately after first terlipressin dose, which may individually predict the patient risk for the development of hyponatremia as other risk factors have rather limited predictive value in real clinical settings.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16019742
- 003
- CZ-PrNML
- 005
- 20160801093650.0
- 007
- ta
- 008
- 160721s2016 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/23362936.2016.7 $2 doi
- 024 7_
- $a 10.14712/23362936.2016.7 $2 doi
- 035 __
- $a (PubMed)26995205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic $7 xx0222901
- 245 10
- $a Terlipressin induced severe hyponatremia / $c M. Šíma, M. Pokorný, F. Paďour, O. Slanař
- 520 9_
- $a Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use - e.g. hyponatremia. We describe a case of a cirrhotic patient with active variceal bleeding treated during two separate hospitalizations with terlipressin. In both drug treatment periods, severe laboratory hyponatremia developed. After terlipressin discontinuation, mineral disbalance corrected rapidly. Positive dechallenge and rechallenge corresponding to the drug administration schedule confirms the causality between terlipressin administration and hyponatremia. Hyponatremia was preceded with substantial fluid retention in both episodes. In this case report we want to highlight the need for fluid balance monitoring immediately after first terlipressin dose, which may individually predict the patient risk for the development of hyponatremia as other risk factors have rather limited predictive value in real clinical settings.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ezofageální a žaludeční varixy $x komplikace $7 D004932
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hematemeze $x farmakoterapie $x etiologie $x patofyziologie $7 D006396
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hyponatremie $x chemicky indukované $x diagnóza $x terapie $7 D007010
- 650 _2
- $a jaterní cirhóza $x komplikace $7 D008103
- 650 _2
- $a lypresin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D008236
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vazokonstriktory $x aplikace a dávkování $x škodlivé účinky $7 D014662
- 650 _2
- $a vodní a elektrolytová nerovnováha $x diagnóza $x etiologie $x prevence a kontrola $7 D014883
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pokorný, Miroslav $u 1st Department of Internal Medicine, Na Bulovce Hospital, Prague, Czech Republic
- 700 1_
- $a Paďour, František, $u 1st Department of Internal Medicine, Na Bulovce Hospital, Prague, Czech Republic $d 1957- $7 xx0075076
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic $7 xx0058262
- 773 0_
- $w MED00013414 $t Prague medical report $x 1214-6994 $g Roč. 117, č. 1 (2016), s. 68-72
- 856 41
- $u https://pmr.lf1.cuni.cz/media/pdf/pmr_2016117010068.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 7 $c 1071 $y 4 $z 0
- 990 __
- $a 20160721 $b ABA008
- 991 __
- $a 20160728093459 $b ABA008
- 999 __
- $a ok $b bmc $g 1156636 $s 944270
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 117 $c 1 $d 68-72 $i 1214-6994 $m Prague Medical Report $n Prague Med. Rep. $x MED00013414
- LZP __
- $b NLK118 $a Pubmed-20160721